Key Developments: Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

11.18USD
2:11pm EDT
Price Change (% chg)

$0.19 (+1.68%)
Prev Close
$10.99
Open
$11.09
Day's High
$11.30
Day's Low
$11.01
Volume
2,049,879
Avg. Vol
6,101,445
52-wk High
$13.80
52-wk Low
$2.26

Search Stocks

Latest Key Developments (Source: Significant Developments)

Achillion Pharmaceuticals Inc Names Milind Deshpande, Ph.D., As President, Chief Executive Officer, Following Announced Retirement Of Michael Kishbauch
Tuesday, 28 May 2013 04:05pm EDT 

Achillion Pharmaceuticals Inc announced that President and Chief Executive Officer Michael D. Kishbauch has decided to retire. In conjunction with this decision, the Board has appointed President of Research and Development and Chief Scientific Officer, Milind Deshpande, Ph.D., to the role of President and Chief Executive Officer and to the Board of Directors. Mr. Kishbauch, who will continue working with management over a three month transition period, will remain a Director on the Achillion Board and is being appointed Chair of a newly-formed Strategy and Corporate Development Committee of the Board.  Full Article

Achillion Pharmaceuticals Inc Announces Closing of Public Offering
Wednesday, 27 Feb 2013 04:30pm EST 

Achillion Pharmaceuticals Inc announced that the underwriters exercised their option to purchase an additional 1,894,410 shares from Achillion in its previously announced underwritten public offering of common stock at a price to the public of $8.40 per share. The offering of 16,894,410 shares of common stock, including the shares purchased upon exercise of the option to purchase additional shares, closed today. The net proceeds to Achillion from the sale of the shares of common stock, after deducting underwriting discounts and commissions and estimated offering expenses, are approximately $133.5 million. Citigroup and Leerink Swann LLC acted as joint book-running managers, and JMP Securities LLC, Piper Jaffray & Co. and Wells Fargo Securities, LLC acted as co-managers for the offering.  Full Article

Achillion Pharmaceuticals Inc Announces Pricing of Public Offering of Common Stock
Thursday, 21 Feb 2013 08:00pm EST 

Achillion Pharmaceuticals Inc announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $8.40 per share. The net proceeds to Achillion from the sale of the shares, after deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $118.5 million. The offering is expected to close on February 27, 2013. Citigroup and Leerink Swann LLC are acting as joint book-running managers, and JMP Securities LLC, Piper Jaffray & Co. and Wells Fargo Securities, LLC are acting as co-managers for the offering. Achillion has granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock. The expected net proceeds to Achillion referenced above do not include any net proceeds that Achillion would receive if the underwriters exercise such option.  Full Article

Achillion Pharmaceuticals Inc Issues FY 2013 EPS Guidance In Line With Analysts' Estimates
Wednesday, 20 Feb 2013 04:08pm EST 

Achillion Pharmaceuticals Inc announced that for fiscal 2013 the net loss per share (EPS) is anticipated to approximate $0.75 per share for fiscal 2013. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report EPS of ($0.75) for fiscal 2013.  Full Article

Achillion Pharmaceuticals Inc Announces Proposed Public Offering Of Common Stock
Wednesday, 20 Feb 2013 04:07pm EST 

Achillion Pharmaceuticals Inc announced that it has commenced an underwritten public offering of $125 million of its common stock. In connection with this offering, Achillion plans to grant the underwriters a 30-day option to purchase additional shares of its common stock. Citigroup and Leerink Swann LLC are acting as joint book-running managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  Full Article

Achillion's hepatitis C drug shows promise in trial

- Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent.

Search Stocks